Loading... Please wait...

Our Newsletter


PHA-793887 | CDK2/5/7 inhibitor

  • PHA-793887.jpg
  • PHA-793887, 400x400px, png
Price:
$169.00
Catalog #:
C7793-5
Quantity:


Product Description

PHA-793887 is an intravenously-administered, inhibitor of cyclin dependent kinases CDK2, CDK5, CDK7, at IC50s of 8 nM, 5 nM, and 10 nM, respectively. [1] As a multi-CDK isoform inhibitor, it was postulated that PHA-793887 might overcome resistance-based mechanisms and lead to enhanced tumor suppression. PHA-793881 was found in Phase I dose-ranging studies to induce severe dose-related hepatotoxicity, thus halting clinical studies. [2]

Additionally, PHA-793887 was found to impair TLR signaling, thus suppressing cytokine production (type 1 interferon, interleukin-6, -10, -12, and TNFa), thereby increasing susceptibility of cancer patients to diseases such as herpes viridae. [3]

PHA-793887 was found to be an effective tool compound for the monitoring of the E2F gene signature pathway. [4]


Technical information:

Chemical Formula:   C19H31N5O2
CAS #:   718630-59-2
Molecular Weight:   361.48
Purity:   >98%
Appearance:   Off White
Chemical Name:   N-(6,6-dimethyl-5-(1-methylpiperidine-4-carbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-methylbutanamide
Solubility:   Up to 100 mM in DMSO
Synonyms:   PHA-793887, PHA 793887, PHA793887

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


Reference:

1. Brasca et al. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem, 2010, 18(5), 1844-1853. Pubmed ID: 20153204
2. Massard et al., A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle 2011, 10(6), 963-970. Pubmed ID: 21368575
3. Zoubir et al., An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae. Cell Cycle 2011, 10(1), 118-126. Pubmed ID: 21200142
4. Locatelli et al., Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study. Mol. Cancer Ther. 2010, 9(5), 1265-1273 Pubmed ID: 21368575

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the PHA-793887 | CDK2/5/7 inhibitor to your wish list.

You Recently Viewed...